US FDA Expectations For Removing Nitrosamines From All APIs, Drug Products
Agency guidance establishes process for ridding unsafe levels of the probable carcinogens from the pharmaceutical supply chain.
You may also be interested in...
The USP has launched an initiative to address the nitrosamine crisis by proposing a new general chapter that outlines a set of analytical methods that manufacturers can use to demonstrate their products are free from unsafe levels of these potential carcinogens. The chapter is aligned with the FDA’s guidance on nitrosamine impurities.
Concerned about another possible nitrosamine scare, US FDA warning letter to Mylan focuses on firm’s failure to control contamination risks of its APIs and its inadequate testing of reused solvents.
EU report on “lessons learnt” from the valsartan crisis calls for tighter GMP controls on API suppliers.